Boston Scientific (BSX) Prelim. Q4 Sales Top Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Boston Scientific (BSX) Prelim. Q4 Sales Top Views
January 9, 2018 6:30 AM EST
MARLBOROUGH, Mass., Jan. 9, 2018 /PRNewswire/ --Â Boston Scientific Corporation (NYSE:Â BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.41 billion during the fourth quarter ended December 31, 2017. This represents growth of approximately 9.9 percent on a reported basis, approximately 8.1 percent on an operational basis (excludes the impact of changes in foreign currency exchange rates) and approximately 6.8 percent on an organic basis, all compared to the prior year period. Organic revenue growth excludes the impact of changes in foreign currency exchange rates and sales from the acquisitions of EndoChoice Holdings, Inc. (EndoChoice) and Symetis SA (Symetis), with no prior year comparable sales.... More
